Low-dose aspirin (ASA) therapy has been shown to alter skin blood flow responses and body temperature during heat stress in middle-aged participants. However, limited research has investigated the influence of aspirin on local sweat responses during continuous exercise and during passive recovery in the heat. PURPOSE: To investigate if, during exercise and/or recovery in the heat, acute ingestion of standard U.S. full-dose (325 mg) or low-dose (81 mg) ASA would alter indices of local sweat rate (SR). METHODS: Seven, healthy male participants (mean ± SD; 27 ± 5 years) completed counter-balanced trials to compare ASA treatments (325 mg ASA and 81 mg ASA) to a control trial (no ASA). A 10 day washout period was used to ensure normal blood platelet restoration between ASA treatments. Participants performed recumbent cycling in the heat (35 °C; 30-40% rH) for 45 min at an intensity initially corresponding to 50% heart rate reserve, followed by a 15 min passive recovery. A capacitance hygrometry capsule was placed on the dorsal aspect of participants forearm and used to continuously measure changes in local SR. RESULTS: ASA did not affect the onset of sweating with respect to core temperature (325 mg, 36.8 ± 0.3 °C; 81 mg, 36.8 ± 0.3 °C; control, 36.8 ± 0.4 °C; P = 0.82), SR sensitivity [(mg·cm−2·min−1)/°C] (325 mg, 0.69 ± 0.20; 81 mg, 0.67 ± 0.22; control, 0.69 ± 0.28; P = 0.94), or peak SR (mg·cm−2·min−1) (325 mg, 0.95 ± 0.24; 81 mg, 0.89 ± 0.18; control, 0.93 ± 0.26; P = 0.42) during exercise. Additionally, ASA did not appear to alter local SR among trials when expressed as percent change (%[INCREMENT]) from the cessation of exercise until the end of passive recovery (325 mg, −45 ± 21%; 81 mg, −53 ± 19%; control, −48 ± 26%; P = 0.70). CONCLUSION: Acute ASA ingestion did not affect thermoregulatory responses during submaximal exercise or passive recovery under the conditions of this investigation. Given the relatively youthful age and health status of present cohort, future research should seek to evaluate the influence of ASA on populations known to be at risk for heat-related illness (e.g., type 2 diabetes, spinal cord injury).
Read full abstract